Promising trends in lung cancer care, but are we overlooking the majority?
作者信息
Sharma Bhavina, Ganti Apar Kishor
机构信息
Division of Oncology-Hematology, Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE 68198, USA.
出版信息
Aging (Albany NY). 2023 Sep 2;15(17):8531-8532. doi: 10.18632/aging.204662.
Abstract
摘要
相似文献
1
Promising trends in lung cancer care, but are we overlooking the majority?肺癌治疗领域呈现出有希望的趋势，但我们是否忽视了大多数患者？
Aging (Albany NY). 2023 Sep 2;15(17):8531-8532. doi: 10.18632/aging.204662.
2
Trends in participant race and sex reporting in lung cancer phase III clinical trials.肺癌 III 期临床试验中参与者种族和性别报告的趋势。
Cancer Rep (Hoboken). 2023 Sep;6 Suppl 1(Suppl 1):e1856. doi: 10.1002/cnr2.1856. Epub 2023 Jul 8.
3
Assessment of quality of life and symptom improvement in lung cancer clinical trials.
Semin Oncol. 2004 Jun;31(3 Suppl 9):1-10. doi: 10.1053/j.seminoncol.2004.04.007.
4
Changing trends in small cell lung cancer.
N C Med J. 1986 Jun;47(6):297-300.
5
Current challenges of lung cancer care in an aging population.老年人群肺癌护理的当前挑战。
Expert Rev Anticancer Ther. 2015;15(12):1419-29. doi: 10.1586/14737140.2015.1096201. Epub 2015 Oct 15.
6
The New Era in Lung Cancer Care.肺癌治疗的新纪元。
Oncology (Williston Park). 2020 Aug 12;34(8):302-304. doi: 10.46883/ONC.2020.3408.0302.
7
Treatment of advanced lung cancer in the elderly.老年晚期肺癌的治疗
Hosp Pract (1995). 2011 Apr;39(2):107-15. doi: 10.3810/hp.2011.04.400.
8
Overview of the randomized phase III trials in non-small cell lung cancer in North America.北美非小细胞肺癌随机III期试验概述。
Semin Oncol. 1997 Jun;24(3 Suppl 8):S8-2-S8-5.
9
The state of the art in non-small cell lung cancer immunotherapy.非小细胞肺癌免疫疗法的最新进展。
Semin Thorac Cardiovasc Surg. 2014 Spring;26(1):26-35. doi: 10.1053/j.semtcvs.2014.02.005. Epub 2014 Mar 26.
10
Promising lung cancer vaccine.有前景的肺癌疫苗。
Environ Health Perspect. 1996 Nov;104(11):1147-8.
本文引用的文献
1
Evaluation of geriatric assessment and management on the toxic effects of cancer treatment (GAP70+): a cluster-randomised study.老年综合评估和管理对癌症治疗毒性作用的评估（GAP70+）：一项集群随机研究。
Lancet. 2021 Nov 20;398(10314):1894-1904. doi: 10.1016/S0140-6736(21)01789-X. Epub 2021 Nov 3.
2
Update of Incidence, Prevalence, Survival, and Initial Treatment in Patients With Non-Small Cell Lung Cancer in the US.美国非小细胞肺癌患者的发病率、患病率、生存率和初始治疗的更新。
JAMA Oncol. 2021 Dec 1;7(12):1824-1832. doi: 10.1001/jamaoncol.2021.4932.
3
Age Is Just a Number: Considerations for Older Adults in Cancer Clinical Trials.年龄只是一个数字：癌症临床试验中老年人的考虑因素。
J Natl Cancer Inst. 2021 Nov 2;113(11):1460-1464. doi: 10.1093/jnci/djab070.
4
Impact of informed consent content and length on recruitment of older adults into a community based primary prevention trial.知情同意书的内容和长度对招募老年人参与一项基于社区的初级预防试验的影响。
Contemp Clin Trials Commun. 2018 Jun 12;11:89-94. doi: 10.1016/j.conctc.2018.05.003. eCollection 2018 Sep.
5
Re-Evaluating Eligibility Criteria for Oncology Clinical Trials: Analysis of Investigational New Drug Applications in 2015.重新评估肿瘤学临床试验的资格标准：2015年研究性新药申请分析
J Clin Oncol. 2017 Nov 20;35(33):3745-3752. doi: 10.1200/JCO.2017.73.4186. Epub 2017 Oct 2.
6
A review of the management of elderly patients with non-small-cell lung cancer.老年非小细胞肺癌患者的管理综述。
Ann Oncol. 2015 Mar;26(3):451-63. doi: 10.1093/annonc/mdu268. Epub 2014 Jul 24.
Zotero 插件